LDLR and central nervous system cancer: These include the low-density lipoprotein receptor (LDLR), EGFR receptors, mesenchymal–epithelial transition factor (MET), transferrin, and HER2/EGFR-tagged/decorated NPs, all of which are believed to facilitate the localization of nanoparticles (NPs) at the glioma injury site [136].